SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

79.2 -4.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

78.5

Max

82.75

Põhinäitajad
By Trading Economics
Sissetulek	-33M 43M
Müük	7.9M 218M
P/E Sektori keskmine	34.025 61.417
Aktsiakasum	0.834
Kasumimarginaal	19.539
Töötajad	1,950
EBITDA	-21M 63M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+12.08% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	130M 4.1B
Eelmine avamishind	83.49
Eelmine sulgemishind	79.2

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

51.1 / N/A Toetus ja vastupanu

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. märts 2026, 19:18 UTC

Suurimad hinnamuutused turgudel

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11. märts 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11. märts 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11. märts 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11. märts 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11. märts 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11. märts 2026, 21:47 UTC

Tulu

Liontown Resources: Market Tailwinds Strengthening Outlook

11. märts 2026, 21:46 UTC

Tulu

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources Says FY26 Guidance Unchanged

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources 1H Unit Operating Costs A$985/Ton

11. märts 2026, 21:44 UTC

Tulu

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Revenue A$207.5 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Net Loss A$184 Million

11. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss $7.5M >VGZ

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss/Shr 6c >VGZ

11. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11. märts 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11. märts 2026, 20:26 UTC

Tulu

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11. märts 2026, 20:19 UTC

Uudisväärsed sündmused

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11. märts 2026, 20:15 UTC

Tulu

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11. märts 2026, 19:31 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11. märts 2026, 19:01 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11. märts 2026, 18:59 UTC

Omandamised, ülevõtmised, äriostud

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

12.08% tõus

12 kuu keskmine prognoos

Keskmine 90 EUR 12.08%

Kõrge 90 EUR

Madal 90 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.